1. Introduction and Background
Growth hormone (GH) is a 191-amino acid polypeptide secreted from somatotroph cells of the anterior pituitary gland in a pulsatile manner, regulated by the opposing actions of hypothalamic growth hormone-releasing hormone (GHRH) and somatostatin. This neuroendocrine axis governs somatic growth, body composition, and metabolic homeostasis through both direct GH signalling and the hepatic production of insulin-like growth factor I (IGF-1) (Pombo et al., 2001). The recognition that exogenous GHRH administration could stimulate endogenous GH release prompted extensive efforts to develop synthetic GHRH analogues with improved pharmacokinetic properties suitable for sustained biological activity.
CJC-1295 emerged from this line of investigation as a modified synthetic analogue of human GHRH(1-29), also designated as growth hormone-releasing factor (GRF)(1-29). Developed by ConjuChem Biotechnologies (Montreal, Canada), CJC-1295 was engineered to overcome the principal limitation of native GHRH, namely its rapid proteolytic degradation in plasma, which confers a half-life of approximately 7 minutes (Jette et al., 2005). Two distinct molecular forms have been investigated: CJC-1295 with Drug Affinity Complex (DAC), which employs a reactive chemical moiety enabling covalent binding to endogenous albumin, and CJC-1295 without DAC (also referred to as modified GRF(1-29) or MOD-GRF(1-29)), which retains the amino acid substitutions conferring protease resistance but lacks the albumin-binding functionality. The distinction between these variants is of considerable pharmacological significance and represents a central theme of this review.
2. Molecular Structure and Mechanism of Action
2.1 Structural Modifications from Native GHRH
Native human GHRH(1-44) exerts its biological activity through the first 29 amino acids of its N-terminal sequence, which are sufficient for full receptor binding and activation. However, the native GHRH(1-29) fragment (known as sermorelin) undergoes rapid enzymatic cleavage in circulation, principally by dipeptidyl peptidase IV (DPP-IV), which cleaves the Ala2-Asp3 bond, rendering the peptide biologically inactive (Henninge et al., 2010). CJC-1295 incorporates four amino acid substitutions at positions 2, 8, 15, and 27 of the GRF(1-29) sequence, specifically designed to confer resistance to DPP-IV and other serum proteases while preserving receptor binding affinity. These substitutions include the replacement of alanine at position 2 with D-alanine, a modification that abolishes the DPP-IV cleavage site, along with additional substitutions that further stabilise the peptide backbone against endopeptidase activity.
2.2 GHRH Receptor Activation and GH Pulsatility
CJC-1295 acts as an agonist at the GHRH receptor (GHRH-R), a class II G protein-coupled receptor expressed on pituitary somatotroph cells. Upon receptor binding, CJC-1295 activates the adenylyl cyclase-cyclic AMP (cAMP) signalling pathway, resulting in elevated intracellular cAMP concentrations that stimulate GH gene transcription, GH synthesis, and GH secretory granule exocytosis. A critical feature of GHRH-mediated GH release is its preservation of physiological pulsatility. Unlike direct GH administration, which establishes supraphysiological and non-pulsatile circulating GH concentrations, GHRH receptor stimulation amplifies the endogenous secretory pulse amplitude while maintaining the ultradian rhythm governed by hypothalamic somatostatin tone.
This preservation of pulsatile GH release is pharmacologically significant because target tissue responsiveness to GH is pattern-dependent. Hepatic IGF-1 production, lipolytic signalling in adipose tissue, and anabolic effects in skeletal muscle are differentially regulated by the amplitude, frequency, and duration of GH pulses. Continuous, non-pulsatile GH exposure leads to GH receptor desensitisation and altered downstream signalling profiles relative to pulsatile delivery (Pombo et al., 2001). The capacity of CJC-1295 to augment endogenous GH pulsatility rather than override it has been proposed as a mechanistic advantage in research applications where maintenance of physiological signalling dynamics is desirable.
3. DAC versus Non-DAC Variants
3.1 Drug Affinity Complex Technology
The DAC moiety represents a reactive chemical group (maleimidopropionic acid) appended to the C-terminus of the modified GRF(1-29) peptide via a lysine linker. Following subcutaneous injection, this reactive group undergoes spontaneous covalent conjugation with Cys34 of circulating serum albumin, a free thiol uniquely available on the albumin surface (Jette et al., 2005). The resulting peptide-albumin bioconjugate benefits from the extended circulatory half-life of albumin (approximately 19 days in humans), dramatically prolonging the effective exposure of the pituitary to GHRH receptor stimulation. Jette et al. (2005) demonstrated that CJC-1295-DAC bioconjugates retained full agonist activity at the GHRH receptor and produced sustained GH elevation in rodent models following a single administration.
3.2 Pharmacokinetic Distinctions
The pharmacokinetic profiles of the two variants differ substantially. CJC-1295 without DAC, while significantly more stable than native GHRH(1-29) owing to its amino acid substitutions, retains a plasma half-life in the range of approximately 30 minutes, necessitating more frequent administration to achieve sustained biological effects (Ionescu and Frohman, 2006). In contrast, CJC-1295 with DAC achieves an effective half-life of approximately 6 to 8 days following albumin conjugation, permitting once- or twice-weekly dosing regimens in clinical investigations.
This pharmacokinetic distinction carries important implications for the pattern of GH release elicited by each variant. The shorter-acting non-DAC form produces discrete, acute elevations in GH secretion that more closely replicate the amplitude-enhanced pulsatile pattern of endogenous GHRH stimulation. The DAC form, by contrast, maintains a sustained, tonic elevation of GHRH receptor activation over several days, which may result in a different GH secretory profile characterised by elevated basal GH concentrations and potentially blunted pulse amplitude due to somatotroph desensitisation (Teichman et al., 2006). Whether these distinct secretory patterns confer differential effects on downstream physiological endpoints remains an active area of investigation within the research community.
4. Pharmacokinetic and Pharmacodynamic Studies
4.1 Extended Half-Life Characterisation
The pharmacokinetic properties of CJC-1295 with DAC were characterised in a pivotal clinical investigation by Teichman et al. (2006), in which healthy adult subjects received single subcutaneous doses ranging from 30 to 120 µg/kg. The study demonstrated dose-dependent increases in circulating GH and IGF-1 concentrations, with mean GH levels elevated 2- to 10-fold above baseline for a period of up to 6 days following a single injection. Peak GH concentrations were observed within 2 hours of administration, consistent with rapid albumin conjugation and prompt initiation of pituitary stimulation. The investigators reported an apparent half-life for the bioconjugate of approximately 5.8 to 8.1 days across dose cohorts, confirming the marked prolongation achieved by the DAC technology (Teichman et al., 2006).
4.2 GH Pulsatility Data
Deconvolution analysis of serial GH sampling data from the Teichman et al. study revealed that CJC-1295 with DAC increased both the number of GH secretory pulses and the mass of GH released per pulse, while maintaining the fundamental pulsatile character of GH secretion. However, interpulse (trough) GH concentrations were also elevated above baseline, indicating a degree of tonic receptor stimulation superimposed upon the pulsatile pattern. This observation has informed ongoing discussion regarding the relative merits of sustained versus intermittent GHRH receptor stimulation in research models (Teichman et al., 2006).
5. IGF-1 Elevation Studies
The capacity of CJC-1295 to elevate circulating IGF-1 concentrations has been documented across both preclinical and clinical investigations. In the human study conducted by Teichman et al. (2006), serum IGF-1 levels increased by 1.5- to 3-fold above baseline values following a single dose of CJC-1295 with DAC, with peak IGF-1 concentrations observed between days 2 and 8 post-administration. Notably, the IGF-1 elevation was more prolonged than the GH response, consistent with the known kinetics of hepatic IGF-1 synthesis in response to sustained GH stimulation. Multiple weekly dosing over a 4-week period produced a progressive, cumulative increase in IGF-1 levels, with mean concentrations reaching 2- to 3-fold above baseline by the end of the treatment period (Teichman et al., 2006).
Preclinical validation of these findings was provided by Alba et al. (2006), who demonstrated that once-daily administration of CJC-1295 normalised somatic growth and restored circulating IGF-1 concentrations in GHRH knockout mice, a model of isolated GHRH deficiency. The treated animals exhibited normalisation of body weight gain, tibial growth plate width, and pituitary GH content, confirming the biological efficacy of CJC-1295-mediated GHRH receptor stimulation in driving the GH-IGF-1 axis (Alba et al., 2006). These preclinical data provided important mechanistic confirmation that the effects observed in human studies were attributable to authentic GHRH receptor agonism rather than non-specific pharmacological activity.
Complementary research by Sackmann-Sala et al. (2009) analysed serum protein profile changes following CJC-1295 administration in healthy adult subjects, documenting alterations consistent with activation of the GH/IGF-1 axis and providing an additional line of evidence for the compound's bioactivity in humans (Sackmann-Sala et al., 2009).
6. Safety Considerations in Research
Published safety data for CJC-1295 derive principally from the clinical pharmacology study by Teichman et al. (2006) and the retrospective analysis by Jetty et al. (2022). In the former, adverse events were predominantly injection site reactions (transient erythema, induration, and pruritus), with systemic effects including flushing, headache, and transient diarrhoea observed in a minority of subjects. No serious adverse events were attributed to the study compound in the published clinical investigations (Teichman et al., 2006).
It is important to acknowledge that the available safety data are limited in both sample size and duration of observation. Long-term safety profiling, particularly with respect to potential effects on glucose homeostasis, neoplastic risk associated with sustained IGF-1 elevation, and pituitary function with chronic GHRH receptor stimulation, has not been adequately characterised in controlled clinical trials. These considerations underscore the investigational nature of CJC-1295 and the requirement for further systematic safety evaluation.
7. Current Research Directions
Contemporary research involving CJC-1295 extends across several areas of active investigation. The combination of GHRH analogues with growth hormone secretagogues (GHS), such as ipamorelin or GHRP-6, represents a prominent research direction, predicated on the rationale that simultaneous engagement of the GHRH receptor and the ghrelin (GHS) receptor produces synergistic amplification of GH release exceeding the additive effects of either agent alone. This synergism arises because GHRH and GHS activate distinct intracellular signalling cascades (cAMP and protein kinase C pathways, respectively) that converge upon the GH secretory apparatus.
The non-DAC variant has attracted particular research interest owing to its capacity to produce acute, discrete GH pulses that more closely approximate physiological secretory dynamics. Studies comparing the biological responses to pulsatile versus sustained GH elevation, including differential effects on hepatic gene expression, adipose tissue metabolism, and skeletal muscle protein synthesis, represent an important frontier for understanding the optimal temporal pattern of GH axis stimulation.
Analytical chemistry investigations have focused on the detection and characterisation of CJC-1295 and its metabolites in biological matrices, driven in part by anti-doping considerations. Henninge et al. (2010) developed mass spectrometric methods for the identification of CJC-1295 in pharmaceutical preparations, contributing to the analytical framework necessary for monitoring and regulatory purposes (Henninge et al., 2010).
In summary, CJC-1295 represents a rationally designed GHRH analogue that has demonstrated the capacity to produce sustained, dose-dependent elevations in both GH and IGF-1 concentrations in preclinical and clinical settings. The distinction between the DAC and non-DAC variants, particularly regarding their differing pharmacokinetic profiles and resultant GH secretory patterns, constitutes a fundamental consideration for research design. While the available evidence supports the pharmacological activity and short-term tolerability of CJC-1295, the absence of large-scale, long-duration controlled trials in the published literature necessitates continued investigation to fully characterise the compound's pharmacological profile and safety in sustained use.